We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
Read MoreHide Full Article
Key Takeaways
TXG's Xenium platform will support a 24-month study to identify breast cancer treatment response biomarkers.
Study will analyze tumor biopsies from 500 patients to uncover cellular factors linked to therapy response.
TXG shares surged 265% year to date, while the Xenium collaboration could expand future opportunities.
10x Genomics (TXG - Free Report) announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics (SPDx) will use its Xenium platform in a collaborative breast cancer biomarker study. The initiative aims to identify biomarkers that could help predict patients' responses to neoadjuvant therapy, potentially supporting the development of more personalized cancer diagnostics.
The collaboration highlights the potential of 10x Genomics' spatial biology technology in advancing clinical research and expanding its applications in oncology. Greater adoption of its platforms by leading research institutions could strengthen TXG's position in the growing spatial biology market and create opportunities for future clinical applications. However, the study remains research-focused, and any commercial benefits will depend on the successful identification and validation of biomarkers and their eventual translation into diagnostic solutions.
TXG Stock Trend Following the News
Year to date, the stock skyrocketed 264.7%, outperforming the industry’s 21.7% growth and the S&P 500’s 10.3% gain.
The collaboration could support 10x Genomics' long-term growth by expanding the clinical research applications of its Xenium platform and strengthening its presence in oncology. The study's focus on identifying biomarkers associated with treatment response could demonstrate the value of spatial biology in advancing precision medicine and encourage broader adoption of the company's technologies among pharmaceutical companies, diagnostic developers and research institutions.
Successful outcomes may also create opportunities for future diagnostic applications, potentially opening new revenue streams beyond research markets. However, meaningful commercial benefits will depend on the successful validation and clinical translation of the study's findings.
TXG currently has a market capitalization of $8.08 billion.
Image Source: Zacks Investment Research
More on the News
The 24-month study will analyze pretreatment tumor biopsy samples from 500 breast cancer patients receiving neoadjuvant therapy, which is administered before surgery to shrink tumors. Researchers will leverage Xenium's spatial profiling capabilities to examine tumor gene expression at cellular resolution and compare the findings with treatment outcomes. The study aims to identify cellular characteristics and biological pathways associated with treatment response and resistance, potentially uncovering biomarkers that conventional diagnostic methods may overlook. The project also offers scope for future expansion to 10x Genomics' Atera platform.
The initiative aligns with 10x Genomics' broader clinical strategy, which focuses on two complementary approaches to advancing single-cell and spatial technologies in diagnostics. The first enables customers to leverage its technologies in translational research to develop potential diagnostic solutions, while the second involves directly advancing selected diagnostic applications by generating evidence to support their future clinical use.
The FUSCC and SPDx collaboration represents the customer-driven approach and complements the company's previously announced academic collaborations in oncology. By combining clinical expertise with detailed insights into tumor biology, the study could lay the groundwork for more precise treatment decisions and improved patient outcomes.
Industry Prospects Favoring the Market
According to MarketandMarkets, the global cancer biomarkers market is projected to grow from USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6% during the forecast period.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News
10x Genomics recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia, marking TXG’s first clinical research initiative into hematologic malignancies.
10x Genomics announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes.
TXG’s Zacks Rank & Other Key Picks
Currently, 10x Genomics carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Bigstock
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
Key Takeaways
10x Genomics (TXG - Free Report) announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics (SPDx) will use its Xenium platform in a collaborative breast cancer biomarker study. The initiative aims to identify biomarkers that could help predict patients' responses to neoadjuvant therapy, potentially supporting the development of more personalized cancer diagnostics.
The collaboration highlights the potential of 10x Genomics' spatial biology technology in advancing clinical research and expanding its applications in oncology. Greater adoption of its platforms by leading research institutions could strengthen TXG's position in the growing spatial biology market and create opportunities for future clinical applications. However, the study remains research-focused, and any commercial benefits will depend on the successful identification and validation of biomarkers and their eventual translation into diagnostic solutions.
TXG Stock Trend Following the News
Year to date, the stock skyrocketed 264.7%, outperforming the industry’s 21.7% growth and the S&P 500’s 10.3% gain.
The collaboration could support 10x Genomics' long-term growth by expanding the clinical research applications of its Xenium platform and strengthening its presence in oncology. The study's focus on identifying biomarkers associated with treatment response could demonstrate the value of spatial biology in advancing precision medicine and encourage broader adoption of the company's technologies among pharmaceutical companies, diagnostic developers and research institutions.
Successful outcomes may also create opportunities for future diagnostic applications, potentially opening new revenue streams beyond research markets. However, meaningful commercial benefits will depend on the successful validation and clinical translation of the study's findings.
TXG currently has a market capitalization of $8.08 billion.
Image Source: Zacks Investment Research
More on the News
The 24-month study will analyze pretreatment tumor biopsy samples from 500 breast cancer patients receiving neoadjuvant therapy, which is administered before surgery to shrink tumors. Researchers will leverage Xenium's spatial profiling capabilities to examine tumor gene expression at cellular resolution and compare the findings with treatment outcomes. The study aims to identify cellular characteristics and biological pathways associated with treatment response and resistance, potentially uncovering biomarkers that conventional diagnostic methods may overlook. The project also offers scope for future expansion to 10x Genomics' Atera platform.
The initiative aligns with 10x Genomics' broader clinical strategy, which focuses on two complementary approaches to advancing single-cell and spatial technologies in diagnostics. The first enables customers to leverage its technologies in translational research to develop potential diagnostic solutions, while the second involves directly advancing selected diagnostic applications by generating evidence to support their future clinical use.
The FUSCC and SPDx collaboration represents the customer-driven approach and complements the company's previously announced academic collaborations in oncology. By combining clinical expertise with detailed insights into tumor biology, the study could lay the groundwork for more precise treatment decisions and improved patient outcomes.
Industry Prospects Favoring the Market
According to MarketandMarkets, the global cancer biomarkers market is projected to grow from USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6% during the forecast period.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News
10x Genomics recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia, marking TXG’s first clinical research initiative into hematologic malignancies.
10x Genomics announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes.
TXG’s Zacks Rank & Other Key Picks
Currently, 10x Genomics carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.